SRS from 1990 through 2008 were identified using a prospectively maintained computer database. Excluded were patients with histologically confirmed WHO Grade II or Grade III tumors, patients with radiation-induced tumors, patients with multiple meningiomas, patients with neurofibromatosis Type 2, and patients who had received either prior or concurrent EBRT. Minnesota requires that consent be obtained from any living patients before their medical records are used for research purposes, and 3 patients refused research authorization. Five patients (4%) had less than 12 months of clinical and radiological follow-up and were excluded. Thus, there were 115 patients included in this study, 46 (40%) of whom had undergone prior surgery and had histologically confirmed WHO Grade I tumors. The median time from resection to SRS was 6 months (range 1-120 months). Sixtynine patients (60%) underwent primary SRS for a presumed histologically benign CSM. The characteristics of the 115 patients are outlined in Table 1 . Thirtyfour patients (30%) had documented tumor growth prior to SRS.
Stereotactic Radiosurgery
Radiosurgery at our institution was performed with the Leksell Gamma Knife (Elekta Instruments). Dose plan ning was primarily performed using stereotactic MRI (n = 112, 97%); 3 patients could not undergo MRI, and in these cases dose planning was performed using stereotactic CT. The goal of dose planning was complete tumor coverage with the prescribed radiation dose while minimizing radiation exposure to the adjacent structures. For patients who had not undergone prior EBRT, it was acceptable for a small portion of the optic nerves and chiasm (2-4 mm 3 ) to receive 10-12 Gy. 34 At the time these patients were treated, this would require a separation of 2-3 mm between the tumor and the optic apparatus. A median of 12 isocenters (range 4-25 isocenters) were used to irradiate a media of 9.3 cm 3 (range 1.3-42.2 cm 3 ). The median tumor margin dose was 16 Gy (range 12-20 Gy). The median maximum radiation dose was 32 Gy (range 24-40 Gy). Of note, only 10 patients (9%) had tumor margin doses below 14 Gy.
A number of changes occurred in our radiosurgical practice in 1997, including personnel changes and modification of the MRI protocol (from 3-mm Gd-enhanced T1-weighted spin-echo sequences to a 1-mm Gd-enhanced 3D spoiled gradient recalled sequence) for radiosurgical treatment of meningioma. Comparison of patients undergoing SRS before January 1997 (n = 38) to those undergoing SRS after January 1997 (n = 77) showed an increase in the median number of isocenters per case (10 vs 12, p = 0.001) despite a reduction in median PIV (12.9 cm 3 vs 8.1 cm 3 , p < 0.05). In addition, the median tumor margin dose (16 Gy vs 15 Gy, p < 0.001) was also lower in patients having radiosurgery after January 1997.
Follow-Up and Statistical Analysis
After SRS, patients were requested to undergo clinical evaluations and MRI at 6, 12, and 24 months posttreatment and at 2-year intervals thereafter. At each follow-up interval, the tumor size was compared with the size on images obtained on the day of SRS and during earlier follow-up examinations. Tumor enlargement of more than 2 mm noted on serial imaging was considered infield progression. Tumor progression adjacent to the irradiated tumor was coded as a marginal progression. New tumor formation away from the irradiated tumor was coded as a distant progression. Local tumor control (LC) was defined as an absence of either local or marginal tumor progression. New neurological deficits occurring after SRS in the absence of tumor progression were considered radiationrelated complications (RRC); deficits that did not resolve were classified as permanent. The median followup after SRS was 89 months (range 12-251 months). Thirty-nine pa tients (34%) had 10 or more years of followup after SRS.
Continuous variables were compared with the Student ttest; nonparametric variables were compared by the chi-square test. Rates of LC and RRC were determined using the Kaplan-Meier method. Univariate testing was performed using the log-rank test on the following variables: age, sex, prior resection, PIV, tumor margin dose, maximum radiation dose, and date of SRS (1996 or earlier vs after 1996). Multivariate testing of the same variables was performed using a Cox proportional hazards model. A p value < 0.05 was considered statistically significant. Statistical analyses were performed using JMP version 9 (SAS Institute Inc.).
Results

Patients' Cranial Nerve Function
The effect of SRS on patients' cranial nerve function 
Tumor Control
Tumor size decreased in 82 patients (71%) and was un changed in 27 patients (24%). Six patients (5%) had tumor progression (in field, n = 3; marginal, n = 3) at a median of 74 months (range 42-145 months) after SRS. The LC rates at 5 and 10 years were 99% and 93%, respectively ( Fig. 1) . No analyzed factor was associated with LC after SRS ( Table 3) . Three patients (3%) had distant tumor progression noted at 76, 81, and 96 months after SRS.
Radiation-Related Complications
Fourteen patients (12%) had permanent RRC at a median onset of 23 months (range 2-146 months). Eleven patients (10%) developed new or worsened cranial nerve deficits including trigeminal dysfunction (n = 9) and diplopia (n = 2). Two patients had ischemic strokes: 1 patient had a frontal and basal ganglia stroke from occlusion of the internal carotid artery within the cavernous sinus, whereas the second patient had a pontine infarct from occlusion of the paramedian branches of the basilar artery (Fig. 2) . One patient developed pituitary insufficiency requiring thyroid and corticosteroid replacement therapy. The 2-year, 5-year, and 10year rates of RRC were 7%, 10%, and 15%, respectively. Multivariate analysis found larger PIV (HR 1.1, 95% CI 1.02-1.2, p = 0.01) to be associated with RRC after SRS ( Table 4 ). The RRC rate for patients with a PIV of 9.3 cm 3 or less was 3% (2 of 58 cases) compared with 21% (12 of 57 cases) for patients with a PIV greater than 9.4 cm 3 (p < 0.01). No patient developed a radiation-induced tumor after SRS.
Additional Treatments
One hundred five patients (91%) required no further procedures after SRS. Three patients (3%) underwent resection of the irradiated CSM because of new or worsened facial pain (n = 2) or infield tumor progression (n = 1). Neither patient who underwent surgery because of pain experienced improvement in the pain postoperatively. The patient with tumor progression was later treated with EBRT (50.4 Gy). All 3 tumors were WHO Grade I (7) * Values represent numbers of patients (%). † Percentages calculated using the number of patients without cranial nerve deficit before SRS as the denominator. ‡ Seventy cranial nerve deficits were noted in 61 patients; 8 patients with incidental tumors. § p < 0.01. meningiomas. One patient (1%) underwent resective surgery for distant tumor progression. One patient (1%) had infield tumor growth and was treated with EBRT (50.4 Gy). One patient (1%) had persistent facial pain and underwent a partial sensory rhizotomy of the trigeminal nerve. Postoperatively, her facial pain was resolved. Four patients (4%) underwent repeat SRS for either marginal (n = 2) or distant (n = 2) tumor progression. Of note, 2 asymptomatic patients (2%) had infield (n = 1) or marginal (n = 1) tumor progression but are being observed due to minimal tumor enlargement and advanced patient age.
Discussion
Management of Patients With CSM
The treatment options for patients with a CSM include observation with serial imaging, microsurgical resection, EBRT, and SRS. When used appropriately, each modality is important in the management of these difficult lesions, and it is not uncommon that a combination of these approaches is needed to achieve tumor control. For example, patients who have large tumors or those who present with visual loss generally require tumor resection to decompress the brainstem and the optic apparatus. However, whereas aggressive removal was once the goal in treating patients with CSM, 4, 5 it is now understood that these tumors frequently invade the adjacent neurovascular structures making complete removal impossible to achieve with acceptable morbidity. 15, 16, 27 As a result, most neurosurgeons now advocate a more conservative operative approach, opting for subtotal tumor removal to minimize the chance of iatrogenic cranial neuropathies. 1, 3, 6, 7, 12 Postoperatively, patients are then typically evaluated for either EBRT or SRS to reduce the chance of later tumor progression. 19, 22 This multimodality approach, often planned in advance of the tumor resection, combines the goals of tumor control and improvement or preservation of neurological function.
More complicated and controversial is the preferred man agement of patients with a small CSM, either at the time of initial diagnosis or postoperatively for residual tu mor. Lee et al. 17 reviewed the histology of 731 patients un dergoing resection of a WHO Grade I meningioma between 1991 and 2004 and found that meningiomas of the midline neuraxis were predominantly of the meningothelial subtype. In 37 (97%) of 38 cases of CSM in their study, the lesions were meningiotheliomas. Although the natural history of the different subtypes of WHO Grade I meningiomas is not known, appreciation of their heterogeneity may prove helpful in future clinical decision making. The same group from the Cleveland Clinic reported 244 pa- At a mean follow-up of 3.8 years, linear tumor growth was noted in 120 tumors (44%). Notably, 114 (74%) of 154 tumors for which the imaging files were available for volumetric analysis showed enlargement. Factors associated with tumor growth included patient age of 60 years or less, lack of calcification, hyperintensity on T2weighted MRI, tumor size greater than 25 mm, and adjacent edema. Meningioma location (skull base vs non-skull base) was not associated with tumor growth by either the linear or volumetric methods. Hashimoto et al. used volumetric analysis of 113 incidentally discovered meningiomas. 9 During an average follow-up period of 46.9 months, 71 tumors (63%) showed more than 15% enlargement. Compared with non-skull base meningiomas, skull base meningiomas grew less frequently (40% vs 75%) and had a longer doubling time (161 months vs 112 months). The authors suggested that patients with skull base tumors can typically be observed safely and longer with sequential MRI than patients with non-skull base meningiomas, with the possible exception of patients with tumors adjacent to the optic nerves in which tumor growth may limit the treatment options later. Nonetheless, the follow-up interval in both of these studies (approximately 4 years) is too short to conclude that observation will be effective for patients with CSM whose life expectancy often extends for 20-30 years, prompting us to treat a number of younger patients with asymptomatic tumors without a period of observation.
When more conservative surgical approaches are used for CSM, a decision must be made postoperatively to either follow patients with serial MRI or to proceed directly to some form of radiation treatment once the patients have recovered from their procedure. In the landmark study by Simpson, 28 the symptomatic tumor recurrence rate after a Grade II resection (macroscopic complete removal of the tumor with coagulation of its dural attachments) was 19%. Patients having a Grade III resection (macroscopic complete removal of the intradural tumor without resection or coagulation of its dural attachments) had a 29% recurrence rate. Mathiesen 12 At a mean follow-up of 13.6 years, 18 patients (62%) had tumor progression. Of 9 patients followed up for 15 or more years, tumor progression was documented in 8 patients (89%). Recently, Sughrue et al. analyzed the recurrence rate in 373 patients who underwent resection of a WHO Grade I meningioma between 1991 and 2008 (median follow-up 3.7 years). 35 No difference was noted in the 5-year progression-free survival rate for patients with a Simpson Grade I (95%), II (85%), III (88%), or IV (81%) resection. Of note, although a large percentage of patients in this series had tumors involving the skull base (51%), patients with CSM were excluded. Comparing their results to earlier studies on this topic, these authors suggested that the application of the Simpson grading system has changed over the years, so that even a Grade IV resection today generally represents a relatively small postoperative tumor burden. In addition, utilization of the updated WHO meningioma grading system would have excluded many patients with Grade II (atypical) meningiomas who were likely included in previous papers on meningioma recurrence rates. Yet, with most studies showing long-term tumor progression rates that exceed 50%, it is not unreasonable to conclude that the majority of patients in their 50s and 60s with WHO Grade I meningiomas and definable tumor remnants on postoperative MRI will show tumor progression at some point after surgery.
Radiosurgery for CSMs
In the current study we report the outcomes of 115 patients who underwent single-fraction SRS at our center between 1990 and 2008 for either documented WHO Grade I or presumed CSM based on the imaging characteristics of their tumor. Excluded from this analysis were patients with WHO Grade II or III meningiomas, multiple meningiomas, and neurofibromatosis Type 2 because tumor control after SRS for these patients has been shown in previous studies to be worse than for patients with sporadic meningiomas. 14, 24, 25, 33, 36 During a follow-up period that extended beyond 20 years for some patients (median 7.4 years), the LC rate was 99% at 5 years and 93% at 10 years. Cranial nerve deficits improved more often in pa tients undergoing primary SRS than in patients who had previously undergone tumor resection (41% vs 20%). The most frequent RRC after SRS was new or worsened trigeminal dysfunction (10%), with diplopia, stroke, and hypopituitarism occurring less commonly. The 2-year, 5-year, and 10-year rates of RRC were 7%, 10%, and 15%, respectively. Despite advances in neuroimaging, dose planning software, and more accurate radiosurgical devices over the past 2 decades, the only analyzed factor that predicted RRC after SRS was a larger PIV. The RRC rate for patients with a PIV of 9.3 cm 3 or less was 3% (2 of 58 cases) compared with 21% (12 of 57 cases) for patients with a PIV greater than 9.4 cm 3 (p < 0.01). The finding of a higher rate of RRC with larger treatment volumes was also noted by Zada et al. 36 They reviewed the cases of 116 patients (with 136 tumors) who underwent single-fraction SRS for benign intracranial meningiomas. Fiftynine tumors (43%) were lo cated in the cavernous sinus. The mean tumor volume of pa tients developing complications was 11 cm 3 compared with 5.7 cm 3 for patients without RRC. Overall, our results are comparable to recent studies on single-fraction SRS of CSM from other centers. These studies document effective tumor control with a low risk of new cranial nerve deficits (Table 5 ). While a clear dose response relationship has been noted for certain radiosurgical indications such as arteriovenous malformations, the radiation dose needed to provide long-term tumor control after single-fraction SRS of benign tumors remains poorly understood. Despite the fact that many centers now use lower tumor margin doses (11-12 Gy) to perform singlefraction SRS of skull base meningiomas, we have continued to treat the majority of patients with slightly higher tumor margin doses (14-15 Gy). Using this dosing regimen, the 10-year LC rate for 251 patients having SRS for imagingdefined meningiomas at our center was 99%. 24 Kollová and colleagues analyzed 368 cases of benign meningioma, including 103 cases of CSM, to determine the optimal radiation dose for single-fraction SRS. 13 They concluded that a tumor margin dose between 12 and 16 Gy is the therapeutic window that provides effective tumor control with a low risk of RRC for patients with benign meningiomas. Lower tumor margin doses were noted by Skeie et al. to be a risk factor for meningioma growth, 29 and lower radiation dose approached but did not achieve significance (p = 0.08) as a factor for LC in the large multicenter study of Santacroce et al. on SRS for the treatment of benign meningioma. 26 So while low tumor margin doses may cause fewer cranial nerve deficits after singlefraction SRS, the risk of neurological injury becomes significantly higher if salvage treatment is subsequently needed because of tumor growth. Recently we have been using single-fraction SRS to treat patients with benign tumors contacting the optic nerves and chiasm but not causing visual loss. In such cases, the majority of the tumor receives a margin dose of 14-15 Gy, while the superior portion of the tumor (typically 2%-5% of the total tumor volume) receives 11-12 Gy. To date, we have not seen tumor progression or visual deficits in patients treated in this manner, but the longterm efficacy of this approach still needs to be determined.
Treatment of Large CSMs
Recognizing that single-fraction SRS provides durable tumor control and a low risk of new cranial nerve deficits for patients with small-volume CSMs, there remains a debate on how to best manage patients with large CSMs. One accepted option is to perform initial nonradical surgery to reduce the tumor size to a volume more compatible with single-fraction SRS. 3, 19, 22 Other options for patients with large tumors include low-dose single-fraction SRS, multisession SRS, or EBRT. Hasegawa ). The 5-year progressionfree survival rate was 94%. Only one patient (0.5%) had an RRC (diplopia). Overall, they felt that 63 patients in their series (32%) would not have been candidates for single-fraction SRS because of tumor size or location and that the rate of RRC was very low, even for patients with large tumors. In a recent paper, Metellus et al. evaluated the outcomes of 53 cases of CSM in which patients were treated with EBRT (median followup 6.9 years).
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The median pretreatment tumor volume was 11.7 cm 3 . All the patients received 52.9 ± 1.8 Gy in 29.4 ± 1.0 fractions. Tumor growth was noted in 2 (4%) of 50 patients, excluding the 3 patients with WHO Grade II meningiomas. One patient (2%) developed diplopia after EBRT. Clinical improvement was more frequent in patients having primary EBRT (20 [71%] of 28 patients) compared with patients having adjuvant EBRT (11 [44%] of 25 patients).
The authors emphasized that EBRT should be considered a complement rather than an alternative to single-fraction . The 5-year actuarial LC rate for patients with WHO Grade I or presumed CSM was 99%. Three patients (4%) had visual loss, but in each case the tumor surrounded the optic nerve. Three other patients developed hypopituitarism and one patient required surgical debulking of radiation necrosis. Considering all the available information, it is clear that the best outcomes for patients with CSM are achieved when their care is directed by neurosurgeons and radia tion oncologists with a combined expertise in microsurgery, SRS, and EBRT.
Study Strengths and Limitations
The strengths of our study include a relatively homogenous patient population with long follow-up (median 89 months). However, our study also has a number of limitations that must be considered when interpreting our results. First, this was a singlecenter, retrospective analysis, and thus, one must be careful about comparing our outcomes directly with outcomes at other centers. Second, although the patient characteristics, treatment variables, and follow-up data were retrieved from a prospectively maintained database, the available information was not detailed enough in every case to precisely categorize pre-and post-SRS cranial nerve function. As a result, we choose to place together oculomotor, trochlear, and abducent nerve palsies in cases of diplopia rather than speculate on the specific cranial nerve that was impaired. Consequently, we were unable to determine the relative radiosensitivity of the different cranial nerves involved in ocular movement. Third, despite a gradual reduction in the prescribed radiation dos es for patients with benign meningiomas treated with SRS at our center over the time frame of this study, 80% of patients received a tumor margin dose of 14-16 Gy. Therefore, our results provide no meaningful information on LC or RRC after low-dose (11-12 Gy), single-fraction SRS of benign CSM.
Conclusions
Single-fraction SRS provides a high rate of tumor con trol with a low risk of cranial nerve deficits or other RRC for patients with small-volume, benign CSMs. Overall, 31% of preSRS cranial nerve deficits improved after SRS. Cranial nerve improvement was more frequent in patients having primary SRS (41%) compared with patients who had prior surgery (20%). The treatment of patients with large CSMs generally requires multimodality therapy that includes advanced skull base surgical techniques, SRS, and EBRT.
